CYP17 inhibitors for prostate cancer therapy. - Abstract - Europe PMC
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer | British Journal of Cancer
CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials Cao Q, Bai P, Shi D, Liao J, Shi H, Xing Y, Chen K, Zhang X -
CYP17 inhibitors in prostate cancer: latest evidence and clinical potential | Semantic Scholar
P450 Signaling | CYP450
CYP17A1 - an overview | ScienceDirect Topics
Androgen receptor antagonism and impact on inhibitors of androgen synthesis in prostate cancer therapy - Njar - Translational Cancer Research
Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective - ScienceDirect
APExBIO - Abiraterone|Potent CYP17 inhibitor|CAS# 154229-19-3
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
Mechanisms of resistance to CYP17 inhibitors. Androgen receptor (AR)... | Download Scientific Diagram
CYP17A1 inhibitor - Wikipedia
Abiraterone Acetate | ≥99%(HPLC) | Selleck | P450 (e.g. CYP17) inhibitor
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents | Nature Reviews Urology
Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer
Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases - ScienceDirect
PDF) CYP17 inhibitors - Abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Abiraterone (Zytiga): Mechanism of Zytiga
CYP17 inhibition as a hormonal strategy for prostate cancer | Nature Reviews Urology
CYP17 inhibitors for prostate cancer therapy - ScienceDirect
Steroidal CYP17 Inhibitors for Prostate Cancer Treatment: From Concept to Clinic | IntechOpen
